The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: Does celecoxib enhance the anti-tumour activity of doxorubicin?

Pharmacological Research

Volumn 50, Issue 5, 2004, Pages 487-498

  Awara, Wageh M ^a   El Sisi, Alaa E ^a   El Sayad, Magda E ^a   Goda, Ahmed E ^a  

^a Tanta University   (Egypt)

Author keywords

Celecoxib; DNA; Doxorubicin; Mammary tumour; Nitric oxide; P glycoprotein; p53

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOXORUBICIN; GLYCOPROTEIN P; RHODAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CARCINOMA CELL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 5344235411     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.04.002     Document Type: Article

References (55)

1. Suh O., Mettlin C., Petrelli N.J. Aspirin use, cancer, and polyps of the large bowel. Cancer. 72:1993;1171-1177
2. Reeves M.J., Newcomb P.A., Trentham-Dietz A., Storer B.E., Remington P.L. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol. Biom. Prev. 5:1996;955-960
3. Li M., Lotan R., Levin B., Tahara E., Lippman S.M., Xu X.C. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol. Biomark. Prev. 9:2000;545-549
4. Rozic J., Chakraborty C., Lala P. Cyclooxygenase inhibitors retard murine mammary tumour progression by reducing tumour cell migration, invasiveness and angiogenesis. Int. J. Cancer. 93:2001;497-506
5. Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res. 88:1997;600-604
6. Ding X.Z., Tong W.G., Adrian T.E. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20:2000;2625-2631
7. Harris R., Alshafie G., Abou-Issa H., Siebert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;2101-2103
8. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2000;2006-2011
9. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403
10. Williams C.S., Watson A.J.M., Sheng H., Helou R., Shao J., DuBois R.N. Celecoxib prevents tumour growth in vivo without toxicity to normal gut: lack of correlation between in vivo and in vitro models. Cancer Res. 60:2000;6045-6051
11. Kopp E., Ghosh S. Inhibition of NF-κ B by sodium salicylate and aspirin. Science. 265:1994;956-959
12. Grilli M., Pizzi M., Memo M., Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kB activation. Science. 274:1996;1383-1385
13. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245
14. Elder D.J., Halton D.E., Hague A., Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3:1997;1679-1683
15. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-beta. Nature. 396:1998;77-80
16. Zhang X., Morham S.G., Langenbach R., Young D.A. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenasenull embryo fibroblasts. J. Exp. Med. 190:1999;451-459
17. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R.B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem. 274:1999;27307-27314
18. 0 Rigas B., Shiff S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med. Hypoth. 54:2000;210-215
19. Carter S.K. Adriamycin: a review. J. Natl. Cancer Inst. 55:1975;1265-1274
20. Wang J. DNA topisomerases. Ann Rev Biochem. 65:1996;635-692
21. Tewey K., Rowe T., Yang L., Halligan B., Liu L. Adriamycin-induced DNA damage medited by mammalian DNA topisomerses II. Science. 226:1984;466-468
22. Capranico G., Zunino F. DNA topisomerase-trapping anti-tumour drugs. Eur. J. Cancer. 28A:1992;2055-2060
23. Lown J., Sim S., Majumdav K., Chaney T. Strand scission of DNA by bound adriamycin and donorubicin in the presence of reducing agents. Biochem. Biophys. Res. Comm. 76:1977;705-710
24. Pirker R., Wallner J., Gotzl M., Gsur A., Geissler K., Havalec L., et al. MDR-1 RNA expression is an independent prognostic factor in acute myeloid leukemia. Blood. 80:1992;557-559
25. Gottesman M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427
26. Gottesman M., Pastan I., Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6:1996;610-617
27. Johnstone R., Ruefli A., Lowe S. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:2002;153-164
28. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr. Drug Targets. 1(1):2000;85-99
29. Ratnasinghe D., Daschner P.J., Anver M.R., Kasprzak B.H., Taylor P.R., Yeh G.C., et al. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance is chemoprevention against multidrug resistance possible? Anticancer Res. 21(3C):2001;2141-2147
30. Osman A., Sayed-Ahmed M., Khayyal M., El Merzebani M. Hyperthermic potentiation of cisplatin on solid Ehrlich carcinoma. Tumouri. 79:1993;268-272
31. Herman T.S., Teicher B.A., Chan V., Collins L.S., Kaufmann M.E., Loh C. Effect of hyperthermia on the action of cis-diammine dichloroplatinum (II), rhodamine 123 (2) [tetrachloro-platinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res. 48(9):1988;2335-2341
32. Al-Shabanah O.A., Osman A.M., Al-Harbi M.M., Al-Gharably N.M., Al-bekairi A.M., El-Merzabani M.M. Effect of hyperthermia on the action of methotrexate against the growth of Ehrlich ascites carcinoma cells. Med. Sci. Res. 24:1996;275-277
33. Attia M., Weiss D.W. Immunology of spontaneous mammary carcinomas in mice infected with mammary tumour virus. Cancer Res. 26:1966;1787-1800
34. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:1956;315-323
35. Gendimenico G.J., Bouquin P.L., Tramposch K.M. Diphenylamine-colorimetric method for DNA assay: a shortened procedure by incubating samples at 50°C. Anal. Biochem. 173(1):1988;45-48
36. Tracey W.R., Tse J., Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice. Pharmacological evaluation of nitric oxide synthase inhibitors. J. Pharmacol. Exp. Ther. 272:1995;1011-1015
37. Manne U., Weiss H.L., Myers R.B., Danner O.K. Nuclear accumulation of p53 in colorectal adenocarcinomas: prognostic importance differs with race and location of tumour. Cancer. 83:1998;2456-2467
38. Sarraf C.E., Bowen I.D. Kinetic studies on murine sarcoma and an analysis of apoptosis. Br. J. Cancer. 54:1988;989-998
39. Bogman K., Peyer A.K., Torok M., Kusters E., Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132:2001;1183-1192
40. Trachtman H., Futterweit S., Mermelstein A., Metzger S., Michael P. Anti-apoptotic effect of L-arginine in cultured rat mesangeal cells. Int. J. Mol. Med. 6:2000;485-489
41. Forrester K., Ambs S., Lupold S.E. Nitric oxide induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild type p53. Proc. Natl. Acad. Sci. 93:1996;2442-2447
42. Ambs S., Ogunfusika M.O., Merriam W.G., Bennett W.P., Billiar T.R., Harris C.C. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc. Natl. Acad. Sci. 95:1998;8823-8828
43. Hamilton L., Warner T. Interactions between iNOS and COX in vivo: investigations using the selective inhibitors 1400W and celecoxib. Br. J. Pharmacol. 125:1998;335-340
44. Tsuji M., Kawano S., Tsuji S., Sawaoka H., Hori M. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716
45. Leahy K., Ornberg R., Wang Y., Zweifel B., Koki A., Masferrer J. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:2002;625-631
46. Pipili-Synetos E., Papageorgiou A., Sakkoula E., Sotiropoulou G., Fotsis T., Karakiulakis G., et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br. J. Pharmacol. 116(2):1995;1829-1834
47. Messmer U.K., Ankarcrona M., Nicotera P., Brune B. p53 Expression in nitric oxide-induced apoptosis. FEBS Lett. 255:1994;23-26
48. Miyashita T., Reed J.C. Tumour suppressor p53 is a direct transcriptional activator of human bax gene. Cell. 80:1995;293-299
49. Badary O.A., Al-Shabanah O.A., Al-Gharably N.M., Elmazar M.M. Effect of Cremophor EL on the pharmacokinetics, anti-tumour activity and toxicity of doxorubicin in mice. Anticancer Drugs. 9(9):1998;809-815
50. Patel R., Attur M.G., Dave M., Abramson S.B., Amin A.R. Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages. J. Immunol. 162:1999;4191-4197
51. Ziemann C., Schäfer D., Rüdell G., Kahl G., Hirsch-Ernst K. The cyclooxygenase system participates in functional MDR-1b overexpression in primary rat hepatocyte cultures. Hepatology. 35:2002;579-588
52. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit. 22(1):2000;137-140
53. Booth C.L., Brouwer K.R., Brouwer K.L.R. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res. 58:1998;3641-3648
54. Smit J.W., Duin E., Steen H., Oosting R., Roggeveld J., Meijer D.K.F. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br. J. Pharmacol. 123:1998;361-370
55. van Asperen J., van Tellingen O., Beijnen J. The role of Mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metabol. Dispos. 28:2000;264-267